Immunovant, Inc. IMVT
37.04 USD +1.33 (+3.72%)
At closeNov 11, 2026, 4:42 PM EST
37.04 0.00 0.00%
After hours · Nov 11, 4:42 PM ET
35.52 Day range 37.59
21.86 52-week range 45.42
- YTD
- +45.71%
- 1 year
- +61.82%
News
zacks.com Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the…
seekingalpha.com Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in…
zacks.com Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.
benzinga.com Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47 Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.
seekingalpha.com Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript Immunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant…
benzinga.com Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA).
benzinga.com Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.
marketbeat.com What Immunovant (IMVT) Said on Its Q2 Earnings Call Roivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 during its fiscal second-quarter earnings call. CEO Matt…
globenewswire.com Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially…
globenewswire.com Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com Immunovant Q1 2027 Earnings Call: Complete Transcript Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
benzinga.com Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
benzinga.com Immunovant Ends Autoimmune Skin Disorder Program Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.
benzinga.com Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
benzinga.com Immunovant Q1 2027 Earnings Call: Complete Transcript On Thursday, Immunovant (NASDAQ:IMVT) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs.…
benzinga.com Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71)…
benzinga.com JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50 JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.- benzinga.com Citigroup Maintains Buy on Immunovant, Raises Price Target to $61 Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.
benzinga.com CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sandler increased price target for TRV, and more.- benzinga.com Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62 Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.
benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.
benzinga.com These Analysts Increase Their Forecasts On Immunovant After Q4 Results Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
benzinga.com B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43 B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $32 to $43.
benzinga.com HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40 HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $35 to $40.
benzinga.com Immunovant Stock Surges Despite Disappointing Earnings Miss Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Down 5%; Lowe's Posts Upbeat Earnings US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe's Companies reported upbeat earnings.
benzinga.com TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 20, 2026 - benzinga.com Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of…
- benzinga.com Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32 Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.
benzinga.com Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other stocks also falling in pre-market trading.- benzinga.com Market-Moving News for April 2nd GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in discussions to acquire the company. IMVT: -17% | Immunovant shares are trading lower after the company
benzinga.com Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo Energy SA, Semilux International Ltd, Visionary Holdings Inc, and more. Losers are PMGC Holdings…- benzinga.com Immunovant's Phase 3 Batoclimab Studies Each Fail To Meet Primary Proptosis Responder Rate Endpoint In Thyroid Eye Disease Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $35 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $35 price target.
- benzinga.com Guggenheim Maintains Buy on Immunovant, Raises Price Target to $44 Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $41 to $44.
- benzinga.com Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76)…
benzinga.com Immunovant Q3 Earnings Assessment - benzinga.com Earnings Scheduled For February 6, 2026
benzinga.com A Look at Immunovant's Upcoming Earnings Report - benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $22 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $16 to $22.
benzinga.com Wolfe Research Upgrades Immunovant to Outperform, Announces $50 Price Target Wolfe Research analyst Andy Chen upgrades Immunovant (NASDAQ:IMVT) from Peer Perform to Outperform and announces $50 price target.- benzinga.com Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $28 Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $18 to $28.
benzinga.com Roivant Signals Major Pipeline Momentum With Accelerated Timelines Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
benzinga.com Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday